[Translation into French and republication of: "Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management"].

Traduction et republication de : « Thrombose veineuse profonde du membre supérieur associée à un cathéter veineux central chez les patients cancéreux : diagnostic et prise en charge thérapeutique ».
Cancer Cathéter veineux central Central venous catheter Deep vein thrombosis Maladie thromboembolique veineuse Thrombose veineuse profonde Venous thromboembolism

Journal

La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383

Informations de publication

Date de publication:
31 May 2024
Historique:
received: 17 11 2023
accepted: 17 11 2023
medline: 2 6 2024
pubmed: 2 6 2024
entrez: 1 6 2024
Statut: aheadofprint

Résumé

Catheter-related thrombosis (CRT) is a relatively frequent and potentially fatal complication arising in patients with cancer who require a central catheter placement for intravenous treatment. In everyday practice, CRT remains a challenge for management; despite its frequency and its negative clinical impact, few data are available concerning diagnosis and treatment of CRT. In particular, no diagnostic studies or clinical trials have been published that included exclusively patients with cancer and a central venous catheter (CVC). For this reason, many questions regarding optimal management of CRT remain unanswered. Due to the paucity of high-grade evidence regarding CRT in cancer patients, guidelines are derived from upper extremity DVT studies for diagnosis, and from those for lower limb DVT for treatment. This article addresses the issues of diagnosis and management of CRT through a review of the available literature and makes a number of proposals based on the available evidence. In symptomatic patients, venous ultrasound is the most appropriate choice for first-line diagnostic imaging of CRT because it is noninvasive, and its diagnostic performance is high (which is not the case in asymptomatic patients). In the absence of direct comparative clinical trials, we suggest treating patients with CRT with a therapeutic dose of either a LMWH or a direct oral factor Xa inhibitor, with or without a loading dose. These anticoagulants should be given for a total of at least 3 months, including at least 1 month after catheter removal following initiation of therapy.

Identifiants

pubmed: 38823999
pii: S0248-8663(24)00580-0
doi: 10.1016/j.revmed.2024.05.018
pii:
doi:

Types de publication

English Abstract Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Investigateurs

Y Benhamou (Y)
A Benmaziane (A)
L Bertoletti (L)
V Bichon (V)
C Bozec (C)
A Cohen (A)
F Couturaud (F)
P Debourdeau (P)
P Dielenseger (P)
É Douriez (É)
A Élias (A)
O Espitia (O)
C Frère (C)
Y Gaboreau (Y)
P Gendron (P)
P Girard (P)
O Hanon (O)
A Idbaih (A)
S Laporte (S)
I Mahé (I)
D Mayeur (D)
P Mismetti (P)
F Moustafa (F)
G Pernod (G)
P-M Roy (PM)
M-È Rouge Bugat (MÈ)
O Sanchez (O)
J Schmidt (J)
F Scotté (F)
M-A Sevestre (MA)

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Auteurs

A Élias (A)

Département de cardiologie et de médecine vasculaire, délégation recherche clinique et innovation, hôpital Sainte-Musse, centre hospitalier intercommunal de Toulon La Seyne-sur-Mer, 83000 Toulon, France; F-CRIN INNOVTE network, Saint-Étienne, France. Electronic address: antoinelias@gmail.com.

P Debourdeau (P)

F-CRIN INNOVTE network, Saint-Étienne, France; Équipe mobile territoriale soins palliatifs, hôpital Joseph-Imbert, Arles, France.

O Espitia (O)

Service de médecine interne et vasculaire, Team III Vascular & Pulmonary Diseases, institut du thorax, CHU de Nantes, Nantes université, Inserm UMR 1087, CNRS UMR 6291, Nantes, France.

M-A Sevestre (MA)

F-CRIN INNOVTE network, Saint-Étienne, France; Service de médecine vasculaire, EA Chimère 7516, CHU d'Amiens, 80054 Amiens, France.

P Girard (P)

F-CRIN INNOVTE network, Saint-Étienne, France; Institut du thorax Curie-Montsouris, institut mutualiste Montsouris, 75014 Paris, France.

I Mahé (I)

F-CRIN INNOVTE network, Saint-Étienne, France; Service de médecine interne, hôpital Louis-Mourier, AP-HP, Colombes, France; Université Paris Cité, Inserm UMR S1140, innovations thérapeutiques en hémostase, Paris, France.

O Sanchez (O)

F-CRIN INNOVTE network, Saint-Étienne, France; Université Paris Cité, Inserm UMR S1140, innovations thérapeutiques en hémostase, Paris, France; Service de pneumologie et de soins intensifs, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France.

Classifications MeSH